Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb dose-ranging study of MK-5442 in postmenopausal women with osteoporosis
2009-012926-35Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of encaleret in osteoporosis (6 arms), sponsored by Merck & Co. Primary endpoints: Lumbar spine areal bone mineral density percent change from baseline at Month 12 and Lumbar spine areal bone mineral density percent change from baseline at Month 24. Started Jun 2009; status: terminated.
02
Drugs
encaleret
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2009-012926-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012926-35.